PerkinElmer Achieves Milestone in Global Deployment of Specialized Information Management Solution for Genetic Screening Laboratories
WALTHAM, Mass.-- (BUSINESS WIRE)--March 13, 2008--PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, today announced that Specimen Gate®, its specialized information management solution for genetic screening laboratories, has been deployed across more than 70 countries, states and provinces worldwide. The Specimen Gate® product portfolio is a critical element of both neonatal and prenatal screening programs, many of which are implemented at the state or national levels of countries around the world, resulting in the identification of thousands of infants at risk of genetic disease each year. As genetic screening programs continue to expand globally, and the demand for world-class information management systems grows, PerkinElmer expects Specimen Gate®-based installations to double by 2010.
The Specimen Gate® product portfolio is a clinically validated informatics solution developed specifically for genetic screening laboratories. The software offers innovative information technology tools and methodologies that allow for the electronic tracking of laboratory workflow, enabling PerkinElmer customers to expand their screening programs while minimizing errors and reducing costs. Specimen Gate® complements PerkinElmer's comprehensive neonatal and prenatal screening systems, which include instruments, reagents, software and consumables.
"PerkinElmer has supplied comprehensive solutions to genetic screening laboratories worldwide for more than 20 years, and has leveraged its unmatched expertise in this market to develop an informatics tool that truly meets the unique needs of genetic screening testing labs," said Robert F. Friel, chief executive officer and president, PerkinElmer, Inc. "As genetic screening continues to expand across the globe, we remain committed to supporting these programs with leading technology to allow for early detection of potentially life-threatening disorders."
The advent of advanced, high-throughput screening technologies worldwide is making it possible for laboratories to dramatically increase the amount of testing they do. However, as the volume of testing increases, so does the complexity of data management. As a result, a growing number of laboratories are demanding scalable software solutions that can accommodate the vast amount of data from modern genetic screening programs. For these customers, PerkinElmer's Specimen Gate® portfolio offers a robust, flexible and customizable solution built specifically to manage the unique screening laboratory workflow.
PerkinElmer has witnessed accelerated adoption of its advanced informatics solution in most parts of the world, with neonatal screening installations in Canada (University of Alberta), Saudi Arabia (King Faisal Specialist Hospital and Research Centre), and Sweden (Centre for Inherited Metabolic Diseases, Karolinska Universitetssjukhuset Huddinge) during the past year. Samples from 3.5 million babies worldwide are currently processed through PerkinElmer's Specimen Gate software each year. In addition, PerkinElmer informatics solutions serve as the foundation of prenatal screening programs for a growing number of countries, such as the Netherlands, which has installed 12 Specimen Gate-based prenatal screening systems to date.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
CONTACT: Investor Relations:
PerkinElmer, Inc.
Michael A. Lawless, 781-663-5659
or
Media Contact:
Brodeur Worldwide
Steve Marchant, 617-587-2864
SOURCE: PerkinElmer, Inc.